By Fineline Cube 
Hangzhou Adamerck Pharmlabs Inc. announced that its independently developed Class 1 innovative drug Aom0498 has received marketing approval from China’s National Medical Products Administration (NMPA), effective July 1, 2026. The new-generation specific neuromuscular blockade reversal agent represents China’s first domestically developed therapy in this critical perioperative category, completing a development journey supported by the National Major New Drug Creation and Development Program across three consecutive national planning periods.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Date | July 1, 2026 |
| Product | Aom0498 |
| Classification | Class 1 innovative drug |
| Indication | Reversal of residual neuromuscular blockade in general anesthesia surgery |
| Development Support | National Major New Drug Creation Program (“12th Five-Year Plan,” “13th Five-Year Plan,” “2020” periods) |
| Origin | First Chinese-developed neuromuscular blockade reversal agent |
Drug Profile & Clinical Significance
Aom0498 – Next-Generation Reversal Agent
- Therapeutic Category: Specific neuromuscular blockade reversal agent
- Primary Benefits:
- Facilitates early extubation in surgical patients
- Reduces postoperative complications from residual neuromuscular blockade
- Enables safer, more precise, and more complete reversal
- Clinical Impact: Addresses critical unmet need in perioperative safety and recovery optimization
- Innovation Status: Represents breakthrough in Chinese pharmaceutical innovation for anesthesia support
Development Heritage
- National Strategic Support: Backed by China’s premier drug innovation initiative across 10+ years
- Domestic Achievement: Eliminates reliance on imported reversal agents in Chinese healthcare system
- Technology Sovereignty: Demonstrates China’s capability to develop complex perioperative therapeutics independently
Market Opportunity & Healthcare Impact
- Surgical Volume: Over 60 million general anesthesia procedures annually in China create massive addressable market
- Current Standard: Limited options for complete neuromuscular blockade reversal, leading to residual complications
- Clinical Burden: Residual neuromuscular blockade affects 30-40% of surgical patients, contributing to respiratory complications and extended recovery
- Healthcare Economics: Early extubation reduces ICU stays and overall hospital costs by an estimated ¥2,000-5,000 per patient
- Reimbursement Priority: High likelihood of rapid inclusion in hospital formularies and provincial reimbursement lists
Strategic Implications
- First-Mover Advantage: Sole domestic supplier in ¥2-3 billion Chinese neuromuscular reversal market
- Export Potential: Quality certification supports potential expansion to other emerging markets
- Portfolio Foundation: Establishes Hangzhou Adamerck as leader in perioperative therapeutics development
- National Recognition: Success validates China’s decade-long investment in indigenous pharmaceutical innovation
Forward-Looking Statements
This brief contains forward-looking statements regarding market adoption and commercial performance. Actual results may differ due to risks including hospital procurement decisions, competitive dynamics, pricing pressures, and healthcare policy changes affecting perioperative pharmaceuticals.-Fineline Info & Tech